You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 再鼎醫藥-SB(9688.HK)升超11%創新高 與Five Prime合作開發藥物獲顯著效果
格隆匯 11-12 10:20
格隆匯11月12日丨次新股再鼎醫藥-SB(9688.HK)今日大幅高開上漲,高見755港元創歷史新高,漲11.13%,總市值659.3億港元。再鼎醫藥合作伙伴Five Prime Therapeutics宣佈,與安慰劑加化療相比Bemarituzumab聯合化療一線治療晚期胃癌或胃食管交界處癌證實具有顯著的無進展生存和總生存獲益。小摩日前指出,再鼎醫藥腫瘤學產品線發展前景樂觀且低風險,預期未來1至2年將有不少新項目推出,加上潛在商業合作有助拓展產品線,宏觀環境及政策對行業發展有利。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account